SCHEMBL30710552

SCHEMBL30710552

CN1C(=O)C(O)(Cc2ccncc2)c2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.67
ATM Q13315 1/20 0.57
RAD52 P43351 1/20 0.57
GAA P10253 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
THPO P40225 1/20 0.51
HPGD P15428 1/20 0.49
RAB9A P51151 1/20 0.49
MAPK1 P28482 3/20 0.49
CBX7 O95931 2/20 0.48
CDY1; CDY1B Q9Y6F8 2/20 0.48
CDYL2 Q8N8U2 1/20 0.48
CDYL Q9Y232 1/20 0.48
MAPT P10636 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18189026 1.00 ALDH1A1 (0.67) ALDH1A1ATMRAD52GAAMEN1
SCHEMBL8295650 0.84 ALDH1A1 (0.66) ALDH1A1ATMRAD52GAAMEN1
Hydrochloric Acid SCHEMBL8300406 0.83 MAPK1 (0.65) ALDH1A1ATMRAD52GAAMEN1
SCHEMBL18189028 0.82 ALDH1A1 (0.50) ALDH1A1ATMGAAMEN1KMT2A
SCHEMBL8807128 0.81 ALDH1A1 (0.74) ALDH1A1ATMMEN1KMT2ACYP1A2
SCHEMBL8299968 0.79 ALDH1A1 (0.66) ALDH1A1ATMGAAMEN1KMT2A
SCHEMBL25890248 0.77 RAD52 (0.68) ALDH1A1RAD52GAAMEN1KMT2A
SCHEMBL8874434 0.77 ATM (0.47) ALDH1A1ATMRAD52GAAMEN1
SCHEMBL8873955 0.75 ATM (0.45) ALDH1A1ATMGAAMEN1KMT2A
SCHEMBL3201165 0.74 ALDH1A1 (0.65) ALDH1A1RAD52GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250381169-A1 METHODS FOR TREATING RENAL DISEASE UNIV ARIZONA (US) 2025-12-18 US disclosed
WO-2023250374-A1 METHODS FOR TREATING RENAL DISEASE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250381169-A1 METHODS FOR TREATING RENAL DISEASE GLS, ARG2, REN ALDH1A1 551/4885ATM 2112/4885RAD52 3363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.